A Phase 2 interventional study of GW642444 and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 5 sites in United States. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-13.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing vilanterol in Asthma — none open to participants now, 2 under way, 2 of them phase 3. vilanterol · Asthma.
Among the 30 studies testing vilanterol in Asthma, this one is the 19th largest by enrollment, is one of 10 that started in 2010, is one of 6 in phase 2, and was the 13th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →None of the 30 studies testing vilanterol in Asthma is open now. The open studies under Asthma, anywhere →
vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 10 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 69 across the 30 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 30 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 177th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 59 in phase 2, and was the 128th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing vilanterol in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing vilanterol in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.
This study will investigate the effect of dosing with 25 μg GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor, in asthmatic subjects aged 5 to 11. GW642444 is currently under development as the long-acting beta-agonist component of a combination product containing an inhaled corticosteroid and a longacting beta-agonist.
Subjects will receive a single dose via a novel dry powder inhaler, then 7 days once-daily repeat dosing following a washout period. The study will be a randomized two-way crossover, with a placebo control. Approximately 26 subjects will be recruited to this study, with the aim that 20 will complete the study. Safety, tolerability, pharmacokinetics and glucose and potassium levels will be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence. Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home). Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods.
Drug: GW642444 · Drug: Placebo
5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence. Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home). Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods.
Drug: GW642444 · Drug: Placebo
GW642444 25 μg; Novel dry powder inhaler
Matching placebo; Novel dry powder inhaler
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General AE/SAE module for a complete list of AEs and SAEs.
Time frame: From the start of study medication until Week 11 (Visit 8)/Early Withdrawal
Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Hematocrit Value at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation). Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Mean Corpuscle Hemoglobin (MCH) Value at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Total Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Peak Expiratory Flow on Day 1, Day 8, and Day 14 of the Respective Treatment Period
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
Time frame: Day 1, Day 8, and Day 14 of the respective treatment period (up to Study Day 49)
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, Day 8, and Day 14 of the Respective Treatment Period
SBP and DBP were measured at Day 1, Day 8, and Day 14 of the respective treatment period. PD=post-dose. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
Time frame: Day 1, Day 8, and Day 14 of the respective treatment period (up to Study Day 49)
Maximum Heart Rate at Day 1 and Day 14 of the Respective Treatment Period
Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Weighted Mean Heart Rate at Day 1 and Day 14 of the Respective Treatment Period
Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Maximum QTcF at Day 1 and Day 14 of the Respective Treatment Period
The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Weighted Mean QTcF at Day 1 and Day 14 of the Respective Treatment Period
The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
AUC(0-t) and AUC(0-8) on Day 14 of the Respective Treatment Period
Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 8 hours AUC(0-8) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Cmax on Day 14 of the Respective Treatment Period
Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Tmax, t1/2, and t at Day 14 of the Respective Treatment Period
tmax is defined as the time to reach the observed maximum concentration, t1/2 is defined as the time required to reduce the plasma concentration to one half its initial value, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Blood Glucose and Potassium on Day 14 of the Respective Treatment Period
Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. . Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.
Time frame: Day 14 of the respective treatment period (up to Study Day 49)
Average Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Distance of Assessment on Day 1 and Day 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Oropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (centimeters cubed \[cm\^3\]) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Inhalation Time on Day 1 and Day 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Inhaled Volume on Day 1 and Day 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Peak Pressure Drop on Day 1 and Day 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Total Emitted Dose (TED) on Day 1 and Day 14 of the Respective Treatment Period
The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Ex-throat Dose (ETD) and ETD <2 Microns on Day 1 and Day 14 of the Respective Treatment Period
The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Participants were enrolled into one of two cohorts based upon age; the younger cohort was enrolled after a review of the safety/pharmacokinetic data of at least six participants from the older cohort. Each participant was assigned to treatment randomly; assignment was not to be influenced by whether participants were in Cohort 1 or Cohort 2.
| Milestone | Sequence 1: VI 25 µg Followed by Placebo | Sequence 2: Placebo Followed by VI 25 µg |
|---|---|---|
| Started | 14 | 14 |
| Completed | 13 | 13 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Met protocol-defined stopping criteria | 1 | 0 |
| Milestone | Sequence 1: VI 25 µg Followed by Placebo | Sequence 2: Placebo Followed by VI 25 µg |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 13 |
| Not completed | 0 | 0 |
| Milestone | Sequence 1: VI 25 µg Followed by Placebo | Sequence 2: Placebo Followed by VI 25 µg |
|---|---|---|
| Started | 13 | 13 |
| Completed | 11 | 13 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General AE/SAE module for a complete list of AEs and SAEs.
| Participants | Placebo | VI 25 µg |
|---|---|---|
| Any AE | 6 | 9 |
| Any SAE | 0 | 0 |
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| 10^9 cells per liter (GI/L) | Placebo | VI 25 µg |
|---|---|---|
| Basophils, n=24, 25 | 0.021 ± 0.0145 | 0.034 ± 0.0185 |
| Eosinophils, n=24, 25 | 0.276 ± 0.3002 | 0.348 ± 0.3458 |
| Lymphocytes, n=24, 25 | 2.404 ± 0.8652 | 2.419 ± 0.8729 |
| Monocytes, n=24, 25 | 0.268 ± 0.1310 | 0.376 ± 0.1419 |
| Total neutrophils, n=24, 25 | 3.354 ± 1.3054 | 3.127 ± 0.9625 |
| Platelets, n=23, 25 | 280.7 ± 54.11 | 279.4 ± 54.71 |
| WBCs, n=24, 25 | 6.32 ± 1.808 | 6.30 ± 1.640 |
Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Grams per liter (g/L) | Placebo | VI 25 µg |
|---|---|---|
| Hemoglobin, n=24, 25 | 133.0 ± 11.30 | 130.7 ± 11.22 |
| MCHC, n=24, 25 | 337.1 ± 5.50 | 338.3 ± 11.60 |
Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| 10^12 cells per liter (TI/L) | Placebo | VI 25 µg |
|---|---|---|
| Reticulocytes, n=24, 25 | 0.05010 ± 0.020696 | 0.05275 ± 0.024571 |
| RBCs, n=24, 25 | 4.60 ± 0.374 | 4.47 ± 0.339 |
Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation). Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| proportion of 1 | Placebo | VI 25 µg |
|---|---|---|
| Hematocrit Value at Day 14 of the Respective Treatment Period | 0.3948 ± 0.03430 | 0.3863 ± 0.02617 |
Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| 10^15 femtoliters (fL) per cell | Placebo | VI 25 µg |
|---|---|---|
| Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period | 86.0 ± 4.08 | 86.6 ± 3.59 |
Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| 10^12 picograms (pg) per cell | Placebo | VI 25 µg |
|---|---|---|
| Mean Corpuscle Hemoglobin (MCH) Value at Day 14 of the Respective Treatment Period | 28.97 ± 1.337 | 29.29 ± 1.464 |
Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| International units per liter (IU/L) | Placebo | VI 25 µg |
|---|---|---|
| ALT, n=22, 25 | 13.9 ± 4.21 | 13.5 ± 3.56 |
| ALP, n=22, 25 | 260.5 ± 109.65 | 273.4 ± 103.51 |
| AST, n=22, 24 | 27.7 ± 6.11 | 25.5 ± 4.52 |
| GGT, n=22, 25 | 14.1 ± 4.12 | 13.6 ± 3.51 |
Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Grams per liter | Placebo | VI 25 µg |
|---|---|---|
| Albumin, n=22, 25 | 42.8 ± 2.95 | 43.2 ± 1.96 |
| Total protein, n=22, 25 | 67.9 ± 4.82 | 68.6 ± 3.16 |
Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Millimoles per liter (mmol/L) | Placebo | VI 25 µg |
|---|---|---|
| Calcium, n=22, 24 | 2.327 ± 0.1357 | 2.359 ± 0.0666 |
| Chloride, n=22, 25 | 105.5 ± 3.90 | 105.1 ± 2.01 |
| CO2 content/bicarbonate, n=22, 24 | 17.6 ± 2.30 | 18.1 ± 1.98 |
| Glucose, n=22, 25 | 4.95 ± 0.510 | 5.04 ± 0.513 |
| Potassium, n=22, 24 | 4.30 ± 0.408 | 4.33 ± 0.242 |
| Sodium, n=22, 25 | 137.7 ± 2.43 | 137.8 ± 2.12 |
| Urea/BUN, n=22, 25 | 4.91 ± 1.368 | 4.48 ± 1.150 |
Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Micromoles per liter (µmol/L) | Placebo | VI 25 µg |
|---|---|---|
| Total bilirubin, n=22, 25 | 6.2 ± 2.22 | 5.8 ± 1.99 |
| Direct bilirubin, n=22, 25 | 1.7 ± 0.94 | 1.2 ± 1.00 |
| Creatinine, n=22, 25 | 39.45 ± 7.653 | 39.35 ± 6.731 |
| Uric acid, n=22, 25 | 241.4 ± 69.51 | 245.6 ± 47.27 |
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
| liters/minute | Placebo | VI 25 µg |
|---|---|---|
| Day 1, Baseline, n=26, 28 | 230.6 ± 72.55 | 233.0 ± 68.55 |
| Day 1, 20 minutes post-dose, n=26, 28 | 237.5 ± 69.65 | 245.6 ± 73.47 |
| Day 8, Pre-dose, n=26, 28 | 232.1 ± 64.76 | 228.8 ± 64.42 |
| Day 8, 20 minutes post-dose, n=25, 28 | 233.8 ± 220.0 | 240.7 ± 65.66 |
| Day 14, Pre-dose, n=24, 26 | 240.3 ± 75.90 | 239.0 ± 72.02 |
| Day 14, 20 minutes post-dose, n=24, 26 | 243.3 ± 75.18 | 248.1 ± 76.20 |
SBP and DBP were measured at Day 1, Day 8, and Day 14 of the respective treatment period. PD=post-dose. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
| Millimeters of mercury (mmHg) | Placebo | VI 25 µg |
|---|---|---|
| Day 1 SBP, Baseline, n=26, 28 | 101.8 ± 6.59 | 102.9 ± 9.21 |
| Day 1 SBP, 10 minutes PD, n=26, 28 | 100.7 ± 7.59 | 102.4 ± 7.69 |
| Day 1 SBP, 30 minutes PD, n=26, 28 | 100.9 ± 9.35 | 103.5 ± 6.89 |
| Day 1 SBP, 45 minutes PD, n=26, 28 | 100.9 ± 7.41 | 103.5 ± 7.05 |
| Day 1 SBP, 74 minutes PD, n=26, 28 | 102.7 ± 7.95 | 104.4 ± 6.81 |
| Day 1 SBP, 2 hours PD, n=26, 28 | 103.3 ± 8.16 | 104.8 ± 7.82 |
| Day 8 SBP, Pre-dose, n=25, 28 | 99.6 ± 6.92 | 103.7 ± 8.64 |
| Day 8 SBP, 30 minutes PD, n=25, 28 | 101.7 ± 7.29 | 102.9 ± 7.31 |
| Day 8 SBP, 1 hour PD, n=25, 28 | 101.8 ± 8.38 | 103.6 ± 7.17 |
| Day 14 SBP, Pre-dose, n=24, 26 | 101.5 ± 9.18 | 103.9 ± 6.15 |
| Day 14 SBP, 10 minutes PD, n=24, 26 | 101.3 ± 9.98 | 103.7 ± 6.70 |
| Day 14 SBP, 30 minutes PD, n=24, 26 | 103.9 ± 8.72 | 102.9 ± 8.91 |
| Day 14 SBP, 45 minutes PD, n=24, 26 | 103.6 ± 7.95 | 103.4 ± 7.03 |
| Day 14 SBP, 75 minues PD, n=24, 26 | 104.9 ± 8.33 | 103.9 ± 6.36 |
| Day 14 SBP, 4 hours PD, n=24, 26 | 102.2 ± 7.80 | 106.0 ± 5.20 |
| Day 14 SBP, 2 hours PD, n=24, 26 | 103.0 ± 6.68 | 102.9 ± 6.42 |
| Day 14 SBP, 8 hours PD, n=24, 26 | 104.7 ± 8.92 | 104.7 ± 7.76 |
| Day 1 DBP, Baseline, n=26, 28 | 62.0 ± 5.12 | 62.1 ± 6.38 |
| Day 1 DBP, 10 minutes PD, n=26, 28 | 62.4 ± 7.16 | 63.5 ± 4.08 |
| Day 1 DBP, 30 minutes PD, n=26, 28 | 62.4 ± 6.55 | 62.6 ± 4.29 |
| Day 1 DBP, 45 minutes PD, n=26, 28 | 63.0 ± 7.93 | 63.3 ± 5.99 |
| Day 1 DBP, 75 minutes PD, n=26, 28 | 63.3 ± 5.74 | 64.4 ± 7.91 |
| Day 1 DBP, 2 hours PD, n=26, 28 | 63.0 ± 4.81 | 63.4 ± 5.49 |
| Day 8 DBP, Pre-dose, n=25, 28 | 63.7 ± 8.17 | 62.8 ± 5.58 |
| Day 8 DBP, 30 minutes PD, n=25, 28 | 62.3 ± 9.19 | 62.4 ± 7.26 |
| Day 8 DBP, 1 hour PD, n=25, 28 | 63.2 ± 6.68 | 62.2 ± 7.90 |
| Day 14 DBP, Pre-dose, n=24, 26 | 60.8 ± 5.70 | 63.8 ± 8.14 |
| Day 14 DBP, 10 minutes PD, n=24, 26 | 60.9 ± 6.55 | 62.7 ± 7.07 |
| Day 14 DBP, 30 minutes PD, n=24, 26 | 62.8 ± 3.83 | 63.7 ± 7.88 |
| Day 14 DBP, 45 minutes PD, n=24, 26 | 61.9 ± 4.05 | 64.5 ± 4.68 |
| Day 14 DBP, 75 minutes PD, n=23, 26 | 63.0 ± 5.12 | 63.6 ± 6.34 |
| Day 14 DBP, 2 hours PD, n=23, 26 | 64.1 ± 7.33 | 63.3 ± 5.50 |
| Day 14 DBP, 4 hours PD, n=23, 26 | 62.3 ± 8.56 | 63.9 ± 6.59 |
| Day 14 DBP, 8 hours PD, n=23, 26 | 63.2 ± 4.78 | 63.3 ± 7.29 |
Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
| Beats per minute | Placebo | VI 25 µg |
|---|---|---|
| Day 1 maximum HR (0-2 hr), n=26, 28 | 83.6 ± 1.44 | 86.1 ± 1.40 |
| Day 14 maximum HR (0-2 hr), n=24, 26 | 84.3 ± 1.38 | 85.0 ± 1.35 |
| Day 14 maximum HR (0-8 hr), n=24, 26 | 88.1 ± 1.45 | 88.6 ± 1.41 |
Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
| Beats per minute | Placebo | VI 25 µg |
|---|---|---|
| Day 1 weighted HR (0-2 hr), n=26, 28 | 76.39 ± 1.311 | 79.20 ± 1.285 |
| Day 14 weighted mean HR (0-2 hr), n=23, 26 | 76.11 ± 1.309 | 77.67 ± 1.264 |
| Day 14 weighted mean HR (0-8 hr), n=23, 26 | 80.54 ± 1.458 | 80.65 ± 1.404 |
The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
| milliseconds | Placebo | VI 25 µg |
|---|---|---|
| Day 1 maximum QTcF (0-2 hr), n=26, 28 | 405.6 ± 2.29 | 406.6 ± 2.22 |
| Day 14 maximum QTcF (0-2 hr), n=24, 26 | 406.1 ± 2.06 | 407.7 ± 2.00 |
| Day 14 maximum QTcF (0-8 hr), n=24, 26 | 407.8 ± 1.87 | 409.2 ± 1.82 |
Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 8 hours AUC(0-8) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.
| picograms*hour per milliliter (pg*hr/mL) | Placebo | VI 25 µg |
|---|---|---|
| AUC(0-t), n=25 | — | 132.8 (96.0 to 183.8) |
| AUC(0-8), n=19 | — | 181.7 (145.0 to 227.7) |
Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.
| picograms per milliliter (pg/mL) | Placebo | VI 25 µg |
|---|---|---|
| Cmax on Day 14 of the Respective Treatment Period | — | 97.44 (64.83 to 146.45) |
tmax is defined as the time to reach the observed maximum concentration, t1/2 is defined as the time required to reduce the plasma concentration to one half its initial value, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.
| hours | Placebo | VI 25 µg |
|---|---|---|
| tmax, n=23 | — | 0.20 (0.00 to 1.00) |
| t1/2, n=14 | — | 3.131 (1.06 to 6.32) |
| t, n=23 | — | 6.00 (1.00 to 8.13) |
Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. . Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.
| Millimoles per liter (mmol/L) | Placebo | VI 25 µg |
|---|---|---|
| Maximum Glucose (0-2 hr), n=24, 26 | 5.55 ± 0.184 | 5.57 ± 0.182 |
| Maximum Glucose (0-8 hr), n=24, 26 | 6.22 ± 0.187 | 6.03 ± 0.183 |
| Weighted Mean Glucose (0-2 hr), n=21, 25 | 5.02 ± 0.114 | 5.06 ± 0.109 |
| Weighted Mean Glucose (0-8 hr), n=19, 24 | 5.26 ± 0.108 | 5.21 ± 0.100 |
| Minimum Potassium (0-2 hr), n=23, 26 | 4.05 ± 0.040 | 4.00 ± 0.038 |
| Minimum Potassium (0-8 hr), n=24, 26 | 3.89 ± 0.060 | 3.87 ± 0.059 |
| Weighted Mean Potassium (0-2 hr), n=19, 22 | 4.21 ± 0.049 | 4.23 ± 0.046 |
| Weighted Mean Potassium (0-8 hr), n=17, 22 | 4.05 ± 0.052 | 4.11 ± 0.049 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| centimeters squared (cm^2) | Placebo | VI 25 µg |
|---|---|---|
| Day 1, n=15, 13 | 5.65 ± 1.834 | 4.42 ± 2.310 |
| Day 14, n=14, 15 | 5.47 ± 1.661 | 5.16 ± 2.139 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| centimeters (cm) | Placebo | VI 25 µg |
|---|---|---|
| Day 1, n=15, 13 | 18.40 ± 1.502 | 18.26 ± 1.824 |
| Day 14, n=14, 15 | 18.46 ± 1.395 | 18.41 ± 1.276 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (centimeters cubed \[cm\^3\]) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| cm^3 | Placebo | VI 25 µg |
|---|---|---|
| Day 1, n=15, 13 | 102.33 ± 32.451 | 78.60 ± 39.296 |
| Day 14, n=14, 15 | 102.26 ± 36.322 | 93.35 ± 37.190 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Liters per minute (L/min) | Placebo | VI 25 µg |
|---|---|---|
| Day 1, Average flow rate, n=23, 25 | 38.84 ± 9.440 | 42.23 ± 10.952 |
| Day 14, Average flow rate, n=23, 25 | 40.45 ± 10.538 | 42.08 ± 10.191 |
| Day 1, PIFR, n=23, 25 | 58.27 ± 14.258 | 61.41 ± 16.513 |
| Day 14, PIFR, n=23, 25 | 60.93 ± 14.901 | 61.79 ± 15.348 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Seconds (sec) | Placebo | VI 25 µg |
|---|---|---|
| Day 1, n=23, 25 | 1.45 ± 0.604 | 1.36 ± 0.551 |
| Day 14, n=23, 25 | 1.35 ± 0.528 | 1.34 ± 0.476 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Liters | Placebo | VI 25 µg |
|---|---|---|
| Day 1, n=23, 25 | 0.93 ± 0.433 | 0.92 ± 0.343 |
| Day 14, n=23, 25 | 0.90 ± 0.426 | 0.95 ± 0.417 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.
| Kilopascal (kpa) | Placebo | VI 25 µg |
|---|---|---|
| Day 1, n=23, 25 | 2.97 ± 1.275 | 3.33 ± 1.632 |
| Day 14, n=23, 25 | 3.23 ± 1.479 | 3.33 ± 1.350 |
The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.
| micrograms | Placebo | VI 25 µg |
|---|---|---|
| Nominal TED | — | 20.28 ± 0.177 |
| Minimum TED | — | 20.24 ± 0.188 |
| Maximum TED | — | 20.31 ± 0.173 |
The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.
| micrograms | Placebo | VI 25 µg |
|---|---|---|
| Nominal ETD | — | 9.00 ± 0.697 |
| Minimum ETD | — | 8.94 ± 0.652 |
| Maximum ETD | — | 9.06 ± 0.747 |
| ETD <2 microns | — | 4.19 ± 1.079 |
| Minimum ETD <2 microns | — | 4.10 ± 1.011 |
| Maximum ETD <2 microns | — | 4.29 ± 1.157 |
The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).
| milliseconds | Placebo | VI 25 µg |
|---|---|---|
| Day 1 weighted mean QTcF (0-2 hr), n=26, 28 | 394.21 ± 2.007 | 396.22 ± 1.960 |
| Day 14 weighted mean QTcF (0-2 hr), n=23, 26 | 395.09 ± 2.122 | 398.03 ± 2.024 |
| Day 14 weighted mean QTcF (0-8 hr), n=23, 26 | 393.43 ± 1.867 | 396.62 ± 1.793 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/26 (0%) | 6/26 (23.1%) |
| VI 25 µg | — | 0/27 (0%) | 9/27 (33.3%) |
| Event | Placebo | VI 25 µg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/26 | 3/27 |
| HeadacheNervous system disorders | 2/26 | 2/27 |
| PyrexiaGeneral disorders | 0/26 | 2/27 |
| SinusitisInfections and infestations | 1/26 | 0/27 |
| Urinary tract infectionInfections and infestations | 1/26 | 0/27 |
| Sinus bradycardiaCardiac disorders | 1/26 | 0/27 |
| DyspepsiaGastrointestinal disorders | 1/26 | 0/27 |
| Conversion disorderPsychiatric disorders | 1/26 | 0/27 |
| DisorientationPsychiatric disorders | 1/26 | 0/27 |
| Otitis mediaInfections and infestations | 0/26 | 1/27 |
| Age, Continuous(Years) | VI 25 µg/Placebo or Placebo/VI 25 µg |
|---|---|
| Mean | 8.0 ± 1.90 |
| Gender(Participants) | VI 25 µg/Placebo or Placebo/VI 25 µg |
|---|---|
| Female | 10 |
| Male | 18 |
| Race/Ethnicity, Customized(Participants) | VI 25 µg/Placebo or Placebo/VI 25 µg |
|---|---|
| African American/African Heritage | 5 |
| White - White/Caucasian/European Heritage | 22 |
| Mixed Race | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 4 months after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilanterol